miconazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
systemic antifungal agents, miconazole derivatives 1800 22916-47-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • miconazole
  • miconazole nitrate
An imidazole antifungal agent that is used topically and by intravenous infusion.
  • Molecular weight: 416.12
  • Formula: C18H14Cl4N2O
  • CLOGP: 5.81
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 0
  • TPSA: 27.05
  • ALOGS: -5.74
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O
1 g O
0.10 g V
1 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 144.18 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 25 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 7.14 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.48 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.08 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 19.75 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 5.181 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.807 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 6.887 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 31.189 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 0.100 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 0.230 % High 1
herg hERG pIC50 5.593 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 28.379 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 81.283 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 0.350 % High 1
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK12,MAPK7,MAPK9,MAPKAPK2,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK 43
kinase-selectivity-class AKT2,AKT3,AXL,BRAF,EIF2AK3,GRK2,PDK4,PIK3CB,SIK2 9
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.442 High 1
mh-clint Mouse hepatocyte intrinsic clearance 44.566 High 1
mppb Mouse plasma protein binding (% unbound) 0.150 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.321 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 0.470 % High 1
rh-clint Rat hepatocyte intrinsic clearance 59.704 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 1.030 % High 1
rppb Rat plasma protein binding (% unbound) 0.130 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 4.395 uM High 1

Approvals:

DateAgencyCompanyOrphan
Jan. 8, 1974 FDA INSIGHT PHARMS
Dec. 30, 1985 PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
International normalised ratio increased 267.15 16.33 109 6786 47207 90574345
Drug interaction 207.91 16.33 170 6725 276283 90345269
Hydronephrosis 85.32 16.33 33 6862 12369 90609183
Cholestasis of pregnancy 57.56 16.33 15 6880 1562 90619990
Vulvovaginal burning sensation 54.54 16.33 16 6879 2579 90618973
Haematuria 47.87 16.33 31 6864 34906 90586646
Lip swelling 47.42 16.33 32 6863 38578 90582974
Haemorrhage subcutaneous 46.20 16.33 15 6880 3381 90618171
Haematoma 44.73 16.33 31 6864 39017 90582535
Cancer pain 43.69 16.33 15 6880 4010 90617542
Tongue necrosis 42.70 16.33 7 6888 69 90621483
Pericardial effusion 39.30 16.33 28 6867 36805 90584747
Tongue haematoma 38.90 16.33 7 6888 124 90621428
Sepsis neonatal 38.42 16.33 9 6886 604 90620948
Encephalitis fungal 34.47 16.33 6 6889 87 90621465
Nail dystrophy 31.58 16.33 9 6886 1309 90620243
Hypokalaemia 31.36 16.33 44 6851 131072 90490480
Cytomegalovirus infection 30.18 16.33 21 6874 26581 90594971
Neuropathy peripheral 29.88 16.33 44 6851 136926 90484626
Axillary pain 26.56 16.33 9 6886 2312 90619240
Vaginal erosion 25.50 16.33 4 6891 29 90621523
Vulvovaginal candidiasis 25.48 16.33 10 6885 3890 90617662
Vulvovaginal pruritus 25.25 16.33 10 6885 3983 90617569
Drug ineffective 25.00 16.33 42 6853 1384256 89237296
Sepsis 24.77 16.33 47 6848 179767 90441785
Premature labour 23.73 16.33 14 6881 13362 90608190
Swelling face 23.58 16.33 30 6865 81322 90540230
Constipation 23.49 16.33 60 6835 280335 90341217
Fungal infection 23.37 16.33 22 6873 42639 90578913
Vulvovaginal pain 23.02 16.33 9 6886 3465 90618087
Drug withdrawal syndrome neonatal 22.70 16.33 8 6887 2311 90619241
Catheter site haemorrhage 22.55 16.33 9 6886 3659 90617893
Urinary tract infection 22.17 16.33 62 6833 305570 90315982
Corynebacterium infection 20.48 16.33 6 6889 962 90620590
Rash erythematous 20.45 16.33 25 6870 65079 90556473
Abdominal pain 20.14 16.33 71 6824 395650 90225902
Jarisch-Herxheimer reaction 20.11 16.33 5 6890 431 90621121
Joint swelling 19.47 16.33 7 6888 503293 90118259
Appendicitis 18.92 16.33 11 6884 10220 90611332
Facial pain 18.80 16.33 12 6883 13170 90608382
Dry skin 18.77 16.33 28 6867 88045 90533507
Seizure 18.71 16.33 38 6857 152591 90468961
Diarrhoea 18.31 16.33 128 6767 939062 89682490
Eosinophilia 18.15 16.33 16 6879 28517 90593035
Fungal sepsis 17.73 16.33 6 6889 1535 90620017
Vulvovaginal swelling 17.13 16.33 5 6890 791 90620761
Conjunctivitis 17.03 16.33 15 6880 26691 90594861
Primary adrenal insufficiency 16.70 16.33 4 6891 295 90621257
Swollen tongue 16.68 16.33 19 6876 45937 90575615
Retroperitoneal haematoma 16.41 16.33 7 6888 3361 90618191

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
International normalised ratio increased 169.69 18.03 84 3774 48084 42569393
Drug interaction 130.08 18.03 139 3719 266860 42350617
Infective keratitis 35.96 18.03 6 3852 55 42617422
Enamel anomaly 33.43 18.03 7 3851 234 42617243
Tooth hypoplasia 32.90 18.03 7 3851 253 42617224
Haematuria 31.28 18.03 32 3826 57767 42559710
Coagulation time prolonged 29.30 18.03 9 3849 1423 42616054
Oedema genital 27.74 18.03 7 3851 538 42616939
Infective corneal ulcer 25.19 18.03 4 3854 26 42617451
Mucormycosis 23.72 18.03 12 3846 7131 42610346
Ocular myasthenia 22.52 18.03 6 3852 571 42616906
Monoplegia 22.37 18.03 8 3850 2026 42615451
Pharyngeal haematoma 20.93 18.03 4 3854 83 42617394
Genital rash 20.35 18.03 6 3852 826 42616651
Haemorrhage subcutaneous 20.32 18.03 8 3850 2638 42614839

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
International normalised ratio increased 342.51 14.89 160 9145 86612 110493382
Drug interaction 254.44 14.89 258 9047 499925 110080069
Hydronephrosis 62.99 14.89 32 9273 20633 110559361
Haematuria 57.49 14.89 51 9254 82954 110497040
Cholestasis of pregnancy 49.58 14.89 13 9292 1252 110578742
Lip swelling 49.45 14.89 38 9267 50629 110529365
Cancer pain 41.31 14.89 17 9288 6755 110573239
Haematoma 38.64 14.89 35 9270 58441 110521553
Tongue necrosis 37.98 14.89 7 9298 128 110579866
Hypokalaemia 35.89 14.89 59 9246 182389 110397605
Enamel anomaly 33.85 14.89 7 9298 237 110579757
Tongue haematoma 33.32 14.89 7 9298 256 110579738
Sepsis neonatal 32.86 14.89 6 9299 104 110579890
Infective keratitis 32.34 14.89 6 9299 114 110579880
Nail dystrophy 31.31 14.89 9 9296 1219 110578775
Tooth hypoplasia 31.19 14.89 7 9298 350 110579644
Seizure 30.12 14.89 61 9244 221124 110358870
Urinary tract infection 30.00 14.89 77 9228 326205 110253789
Constipation 28.43 14.89 80 9225 357706 110222288
Pericardial effusion 27.92 14.89 29 9276 57188 110522806
Oedema genital 27.11 14.89 7 9298 635 110579359
Vulvovaginal candidiasis 26.17 14.89 10 9295 3275 110576719
Drug withdrawal syndrome neonatal 26.02 14.89 6 9299 339 110579655
Infective corneal ulcer 25.48 14.89 4 9301 26 110579968
Axillary pain 24.72 14.89 9 9296 2577 110577417
Premature labour 24.49 14.89 13 9292 9159 110570835
Dry skin 24.17 14.89 37 9268 107616 110472378
Sepsis 23.88 14.89 71 9234 327275 110252719
Coagulation time prolonged 23.67 14.89 9 9296 2908 110577086
Catheter site haemorrhage 23.62 14.89 11 9294 5869 110574125
Ocular myasthenia 21.18 14.89 6 9299 772 110579222
Haemorrhage subcutaneous 21.13 14.89 10 9295 5529 110574465
Cytomegalovirus infection 20.35 14.89 24 9281 54420 110525574
Labelled drug-drug interaction medication error 20.26 14.89 18 9287 29284 110550710
Swelling face 19.70 14.89 31 9274 92290 110487704
Neuropathy peripheral 19.32 14.89 45 9260 179232 110400762
Premature baby 19.25 14.89 9 9296 4846 110575148
Vulvovaginal burning sensation 19.04 14.89 7 9298 2062 110577932
Pharyngeal haematoma 18.50 14.89 4 9301 168 110579826
Rash erythematous 18.19 14.89 28 9277 81804 110498190
Tongue fungal infection 18.00 14.89 4 9301 191 110579803
Nasal dryness 17.86 14.89 9 9296 5697 110574297
Blood creatinine increased 17.66 14.89 44 9261 182845 110397149
Dementia 17.18 14.89 17 9288 31656 110548338
Breast cancer metastatic 17.00 14.89 11 9294 11170 110568824
Cellulitis 16.25 14.89 34 9271 125982 110454012
Pneumomediastinum 15.93 14.89 8 9297 5028 110574966
Drug ineffective 15.91 14.89 70 9235 1520470 109059524
Benign vulval neoplasm 15.84 14.89 3 9302 64 110579930
Corynebacterium infection 15.61 14.89 6 9299 1994 110578000
Contusion 15.49 14.89 49 9256 233312 110346682
Allergic cough 15.34 14.89 5 9300 1030 110578964

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A01AB09 ALIMENTARY TRACT AND METABOLISM
STOMATOLOGICAL PREPARATIONS
STOMATOLOGICAL PREPARATIONS
Antiinfectives and antiseptics for local oral treatment
ATC A07AC01 ALIMENTARY TRACT AND METABOLISM
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
INTESTINAL ANTIINFECTIVES
Imidazole derivatives
ATC D01AC02 DERMATOLOGICALS
ANTIFUNGALS FOR DERMATOLOGICAL USE
ANTIFUNGALS FOR TOPICAL USE
Imidazole and triazole derivatives
ATC D01AC52 DERMATOLOGICALS
ANTIFUNGALS FOR DERMATOLOGICAL USE
ANTIFUNGALS FOR TOPICAL USE
Imidazole and triazole derivatives
ATC G01AF04 GENITO URINARY SYSTEM AND SEX HORMONES
GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
Imidazole derivatives
ATC J02AB01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
Imidazole derivatives
ATC S02AA13 SENSORY ORGANS
OTOLOGICALS
ANTIINFECTIVES
Antiinfectives
FDA CS M0002083 Azoles
FDA EPC N0000175487 Azole Antifungal
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006727 Hormone Antagonists
MeSH PA D058888 14-alpha Demethylase Inhibitors
MeSH PA D065088 Steroid Synthesis Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D065688 Cytochrome P-450 CYP2C9 Inhibitors
MeSH PA D065692 Cytochrome P-450 CYP3A Inhibitors
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:75282 ergosterol biosynthesis inhibitor
CHEBI has role CHEBI:82891 glucocorticoid receptor antagonist
CHEBI has role CHEBI:35718 antifungal agent
CHEBI has role CHEBI:86327 antifungal drug

Related Drugs by ATC class:

A01AB Antiinfectives and antiseptics for local oral treatment 22 drugs
amphotericin Bbenzoxonium chloridecetylpyridiniumchlorhexidinechlortetracyclineclotrimazoledomiphendoxycyclinehexetidinehydrogen peroxidemepartricinmetronidazole show all 22 →
D01AC Imidazole and triazole derivatives 20 drugs
bifonazolechlormidazoleclotrimazoleeberconazoleeconazoleefinaconazolefenticonazolefluconazoleflutrimazoleisoconazoleketoconazolelanoconazole show all 20 →
G01AF Imidazole derivatives 16 drugs
azanidazolebutoconazoleclotrimazoleeconazolefenticonazoleflutrimazoleisoconazoleketoconazolemetronidazoleomoconazoleornidazoleoxiconazole show all 16 →
J02AB Imidazole derivatives 1 drug
ketoconazole
S02AA Antiinfectives 17 drugs
acetic acidaluminium acetotartrateboric acidcefmenoximechloramphenicolchlorhexidineciprofloxacinclioquinolfosfomycingentamicinhydrogen peroxideneomycin show all 17 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Tinea pedis indication 6020002 DOID:12403
Candidiasis of skin indication 49883006
Pityriasis versicolor indication 56454009 DOID:9060
Candidal vulvovaginitis indication 72605008 DOID:2272
Candidiasis of mouth indication 79740000 DOID:14262
Tinea corporis indication 84849002
Diaper rash indication 91487003
Tinea cruris indication 399029005
Onychomycosis due to dermatophyte indication 402134005
Deep mycosis indication 716203000
Oropharyngeal Candidiasis indication
Paronychia off-label use 71906005 DOID:13117
Disease of liver contraindication 235856003 DOID:409




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Infections caused by Microsporum canis Indication
Cats Infections caused by Microsporum gypseum Indication
Cats Infections caused by Trichophyton mentagrophytes Indication
Dogs Infections caused by Microsporum canis Indication
Dogs Infections caused by Microsporum gypseum Indication
Dogs Infections caused by Trichophyton mentagrophytes Indication

🐶 Veterinary products

ProductApplicantIngredients
Conofite Cream 2% Intervet Inc. 1
Conofite Lotion 1% Intervet Inc. 1
Surolan Elanco US Inc. 3
Easotic Virbac AH Inc. 3
Miconosol Med-Pharmex Inc. 1
Priconazole Lotion 1% and Spray 1% First Priority Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.49 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.25%;81.35%;15% VUSION MYLAN N021026 Feb. 16, 2006 RX OINTMENT TOPICAL 8147852 March 30, 2028 USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR Ki 5.14 DRUG MATRIX
Prostaglandin G/H synthase 2 Enzyme IC50 4.59 DRUG MATRIX
Cannabinoid receptor 1 GPCR Ki 4.78 DRUG MATRIX
Mu-type opioid receptor GPCR Ki 5.61 DRUG MATRIX
D(1A) dopamine receptor GPCR Ki 5.51 DRUG MATRIX
D(2) dopamine receptor GPCR Ki 5.38 DRUG MATRIX
Adenosine receptor A2a GPCR Ki 5.10 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 5.83 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2 Ion channel WOMBAT-PK
Cytochrome P450 3A4 Enzyme IC50 7 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 6.38 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.54 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 5.18 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 5.95 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 5.45 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 5.56 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.30 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 5.79 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 5.96 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.18 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 6.02 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 5.81 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 6.18 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 6.35 DRUG MATRIX
Beta-3 adrenergic receptor GPCR Ki 5.39 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.87 DRUG MATRIX
Cytochrome P450 2D6 Enzyme IC50 6 DRUG MATRIX
Adenosine receptor A1 GPCR Ki 5.14 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.80 DRUG MATRIX
D(4) dopamine receptor GPCR Ki 5.27 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 5.83 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 5.58 DRUG MATRIX
Delta-type opioid receptor GPCR Ki 5.92 DRUG MATRIX
Acetylcholinesterase Enzyme IC50 4.73 DRUG MATRIX
Cytochrome P450 2C9 Enzyme IC50 6.70 DRUG MATRIX
Aromatase Enzyme IC50 6.22 CHEMBL
Epidermal growth factor receptor Kinase IC50 4.53 DRUG MATRIX
Substance-P receptor GPCR Ki 5.43 DRUG MATRIX
Steroid 17-alpha-hydroxylase/17,20 lyase Enzyme Ki 6.61 CHEMBL
Cytochrome P450 2C19 Enzyme IC50 7.80 DRUG MATRIX
Alkaline phosphatase, tissue-nonspecific isozyme Enzyme EC50 4.15 CHEMBL
Tyrosine-protein kinase Fyn Kinase IC50 5.38 DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 4.56 DRUG MATRIX
Thromboxane-A synthase Enzyme IC50 6.58 DRUG MATRIX
Lanosterol 14-alpha demethylase Enzyme IC50 6.70 CHEMBL
Indoleamine 2,3-dioxygenase 1 Enzyme IC50 5.42 CHEMBL
Type-2 angiotensin II receptor GPCR Ki 5.11 DRUG MATRIX
Substance-K receptor GPCR Ki 5.79 DRUG MATRIX
Melanocortin receptor 4 GPCR Ki 4.92 DRUG MATRIX
Melanocortin receptor 5 GPCR Ki 4.67 DRUG MATRIX
Melanocortin receptor 3 GPCR Ki 4.79 DRUG MATRIX
Malate dehydrogenase cytoplasmic Enzyme IC50 4.60 CHEMBL
Calcium release-activated calcium channel protein 1 Ion channel IC50 4.57 CHEMBL
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase Enzyme IC50 5.82 CHEMBL
Lanosterol 14-alpha demethylase Enzyme INHIBITOR CHEMBL CHEMBL
Beta-lactamase Enzyme IC50 4.40 CHEMBL
Androgen receptor Transcription factor Ki 5.33 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 5.03 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.69 DRUG MATRIX
Progesterone receptor Transcription factor Ki 5.71 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR IC50 4.94 CHEMBL
Acetylcholinesterase Enzyme IC50 4.67 CHEMBL
Aromatase Enzyme EC50 6.40 CHEMBL
Cholinesterase Enzyme IC50 5.17 CHEMBL
Lanosterol 14-alpha demethylase Enzyme Kd 6.70 CHEMBL
Indoleamine 2,3-dioxygenase 2 Enzyme IC50 5.17 CHEMBL
Mycocyclosin synthase Enzyme Kd 7.14 CHEMBL
Indoleamine 2,3-dioxygenase 1 Enzyme IC50 4.75 CHEMBL
Fatty acid hydroperoxide lyase, chloroplastic Enzyme IC50 4.19 CHEMBL
Sodium/potassium-transporting ATPase subunit alpha-2 Ion channel IC50 4.72 DRUG MATRIX

External reference:

IDSource
4018555 VUID
N0000146875 NUI
D00416 KEGG_DRUG
22832-87-7 SECONDARY_CAS_RN
4018554 VANDF
4018555 VANDF
C0025942 UMLSCUI
CHEBI:6923 CHEBI
CHEMBL91 ChEMBL_ID
CHEMBL1559 ChEMBL_ID
D008825 MESH_DESCRIPTOR_UI
DB01110 DRUGBANK_ID
4189 PUBCHEM_CID
2449 IUPHAR_LIGAND_ID
2728 INN_ID
7NNO0D7S5M UNII
42790 RXNORM
1135 MMSL
36502 MMSL
5112 MMSL
5113 MMSL
7143 MMSL
d00155 MMSL
002918 NDDF
002919 NDDF
372738006 SNOMEDCT_US
42720001 SNOMEDCT_US
60727003 SNOMEDCT_US
7NNO0D7S5M INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Good Sense Miconazole 7 HUMAN OTC DRUG LABEL 1 0113-0214 CREAM 2 g VAGINAL ANDA 17 sections
good sense miconazole 7 HUMAN OTC DRUG LABEL 1 0113-0825 CREAM 2 g VAGINAL ANDA 17 sections
GOOD SENSE MICONAZOLE 3 HUMAN OTC DRUG LABEL 1 0113-7110 CREAM 40 mg VAGINAL ANDA 17 sections
Selan Antifungal HUMAN OTC DRUG LABEL 1 0159-2500 CREAM 2 g TOPICAL OTC Monograph Drug 12 sections
Selan Antifungal HUMAN OTC DRUG LABEL 1 0159-2500 CREAM 2 g TOPICAL OTC Monograph Drug 12 sections
Desenex HUMAN OTC DRUG LABEL 1 0316-0225 POWDER 20 mg TOPICAL OTC Monograph Drug 11 sections
Desenex HUMAN OTC DRUG LABEL 1 0316-0225 POWDER 20 mg TOPICAL OTC Monograph Drug 11 sections
Desenex Antifungal Foot Cream HUMAN OTC DRUG LABEL 1 0316-0255 CREAM 20 mg TOPICAL OTC Monograph Drug 12 sections
Zeasorb Athletes Foot HUMAN OTC DRUG LABEL 1 0316-8000 POWDER 20 mg TOPICAL OTC Monograph Drug 11 sections
Zeasorb Athletes Foot HUMAN OTC DRUG LABEL 1 0316-8000 POWDER 20 mg TOPICAL OTC Monograph Drug 11 sections
Zeasorb Jock Itch HUMAN OTC DRUG LABEL 1 0316-8001 POWDER 20 mg TOPICAL OTC Monograph Drug 11 sections
Zeasorb Jock Itch HUMAN OTC DRUG LABEL 1 0316-8001 POWDER 20 mg TOPICAL OTC Monograph Drug 11 sections
Miconazole 7 HUMAN OTC DRUG LABEL 1 0363-0730 CREAM 20 mg VAGINAL ANDA 17 sections
miconazole 3 HUMAN OTC DRUG LABEL 1 0363-2070 CREAM 40 mg VAGINAL ANDA 17 sections
Miconazole Nitrate HUMAN OTC DRUG LABEL 1 0363-4208 SPRAY 3 g TOPICAL OTC Monograph Drug 14 sections
Miconazole Nitrate HUMAN OTC DRUG LABEL 1 0363-4208 SPRAY 3 g TOPICAL OTC Monograph Drug 14 sections
Miconazole Nitrate 2% HUMAN OTC DRUG LABEL 1 0363-5353 AEROSOL, SPRAY 1.30 g TOPICAL OTC Monograph Drug 14 sections
Miconazole Nitrate 2% HUMAN OTC DRUG LABEL 1 0363-5353 AEROSOL, SPRAY 1.30 g TOPICAL OTC Monograph Drug 14 sections
Miconazole Nitrate HUMAN OTC DRUG LABEL 1 0363-7418 AEROSOL, SPRAY 2.60 g TOPICAL OTC Monograph Drug 14 sections
Miconazole Nitrate HUMAN OTC DRUG LABEL 1 0363-7418 AEROSOL, SPRAY 2.60 g TOPICAL OTC Monograph Drug 14 sections
Foot Powder HUMAN OTC DRUG LABEL 1 0363-7999 POWDER 20 mg TOPICAL OTC Monograph Drug 13 sections
Foot Powder HUMAN OTC DRUG LABEL 1 0363-7999 POWDER 20 mg TOPICAL OTC Monograph Drug 13 sections
Jock Itch Powder HUMAN OTC DRUG LABEL 1 0363-9223 POWDER 20 mg TOPICAL OTC Monograph Drug 13 sections
VUSION HUMAN PRESCRIPTION DRUG LABEL 3 0378-8222 OINTMENT 2.50 mg TOPICAL NDA authorized generic 26 sections
VUSION HUMAN PRESCRIPTION DRUG LABEL 3 0378-9730 OINTMENT 2.50 mg TOPICAL NDA 26 sections
Miconazole Nitrate HUMAN PRESCRIPTION DRUG LABEL 1 0472-1738 SUPPOSITORY 200 mg VAGINAL ANDA 16 sections
MICONAZOLE Nitrate 2% Cream ANTIFUNGAL HUMAN OTC DRUG LABEL 1 0536-1375 CREAM 2 g TOPICAL OTC Monograph Drug 10 sections
fungoid tincture HUMAN OTC DRUG LABEL 1 0884-0293 TINCTURE 20 mg TOPICAL OTC Monograph Drug 12 sections
Miconazole 7 HUMAN OTC DRUG LABEL 1 0904-7734 CREAM 20 mg VAGINAL ANDA 16 sections
Miconazole Nitrate Antifungal Powder HUMAN OTC DRUG LABEL 1 10135-720 POWDER 2 g TOPICAL OTC Monograph Drug 10 sections